🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for ALK Positive Non-small Cell Lung Cancer

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site📍 Beijing Peking Union Medical College Hospital · Tests: Ensartinib Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877Phase 21 site📍 Jinan Pingping Song · Tests: WX-0593 Tablets Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Ensartinib Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer NCT07415005Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Lorlatinib A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib NCT06378892Phase 29 sites📍 Aviano📍 Florence📍 Lido di Camaiore Centro di Riferimento Oncologico - Aviano · Tests: Lorlatinib AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer NCT07617337Phase 17 sites📍 Houston📍 Nagoya📍 Kashiwa Chugai Pharmaceutical · Tests: AQUA07, Lorlatinib Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context NCT06487078NA32 sites📍 Toulouse📍 Paris📍 Aix-en-Provence Pfizer · Tests: Lorlatinib Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC NCT05122806NA46 sites📍 Saint-Denis📍 Aix-en-Provence📍 Amiens Groupe Francais De Pneumo-Cancerologie · Tests: RNAseq Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006Phase 1, Phase 21 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Alectinib Oral Product A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016Phase 117 sites📍 Fullerton📍 Orange📍 Edwards Astellas Pharma Global Development, Inc. · Tests: gilteritinib Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy NCT06862869n/a44 sites📍 Zhanjiang📍 Guangzhou📍 Kaifeng Hoffmann-La Roche · Tests: Alectinib Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935NA1 site📍 Boston Massachusetts General Hospital · Tests: POISE Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086Phase 21 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Loratinib Gilteritinib for the Treatment of ALK NSCLC NCT06225427Phase 13 sites📍 Los Angeles📍 Washington D.C.📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients NCT06361589n/a1 site📍 Chengdu Sichuan Cancer Hospital and Research Institute · Tests: Lorlatinib Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109Phase 3159 sites📍 Glendale📍 Newport Beach📍 Orange Nuvalent Inc. · Tests: Neladalkib (NVL-655), Alectinib A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC NCT07491497Phase 1, Phase 216 sites📍 San Francisco📍 Aurora📍 Boston TRIANA Biomedicines, Inc. · Tests: TRI-611 Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) NCT07354061Phase 1, Phase 21 site📍 Xi’an Tang-Du Hospital · Tests: Ensartinib + Chemotherapy Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib NCT07374614n/a1 site📍 Shenzhen Peking University Shenzhen Hospital · Tests: Iruplinalkib tablets Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT NCT05236946Phase 31 site📍 Mumbai Tata Memorial Hospital · Tests: Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor Study of NXP900 With Lorlatinib in ALK+ Lung Cancer NCT07784959Phase 11 site📍 Fairfax Nuvectis Pharma, Inc. · Tests: NXP900, Lorlatinib Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib NCT07633626n/a1 site📍 Bogotá Centro de Tratamiento e Investigación sobre Cáncer, Luis Ca…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy